Investing.com – Regeneron Pharma (NASDAQ:) reported third quarter that beat analysts’ expectations on Tuesday and revenue that topped forecasts.
The firm reported earnings per share of $6.67 on revenue of $2.05B. Analysts polled by Investing.com expected EPS of $6.41 on revenue of $1.99B. That compared to EPS of $5.87 on revenue of $1.66B in the same period a year earlier. The company had reported EPS of $6.02 on revenue of $1.93B in the previous quarter.
Regeneron Pharma follows other major Healthcare sector earnings this month
On October 15, J&J reported third quarter EPS of $2.12 on revenue of $20.73B, compared to forecasts of EPS of $2.01 on revenue of $20.08B.
Merck&Co earnings beat analysts’ expectations on October 29, with third quarter EPS of $1.51 on revenue of $12.4B. Investing.com analysts expected EPS of $1.24 on revenue of $11.64B
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.